Hepatitis B virus (HBV) remains one of the major causes of chronic liver disease and hepatocellular carcinoma worldwide. Infection with hepatitis D virus (HDV) in individuals already infected with HBV leads to coinfection or superinfection, which significantly worsens the clinical outcome. This study reviews clinical and microbiological characteristics of HBV/HDV coinfection with a focus on available epidemiological data from Uzbekistan. The aim is to highlight virological interactions, disease progression, and implications for diagnosis and prevention.

Hepatitis B, Hepatitis D, coinfection, liver cirrhosis, Uzbekistan, microbiology.

World Health Organization. Global Hepatitis Report. Geneva: WHO; 2023.

El-Serag HB. Hepatitis viruses and liver cancer. Gastroenterology. 2020.

Tu T, et al. Hepatitis B virus-related hepatocellular carcinoma. Front Oncol. 2021.

Zhou J, et al. The HBx protein in carcinogenesis. Cell Mol Immunol. 2020.

Forner A, et al. Hepatocellular carcinoma. Lancet. 2018.

Nishida N, et al. MicroRNAs in hepatitis and cancer. Front Med. 2019.

Sugimoto K. Gut microbiota in liver disease. Hepatol Res. 2021.

Terrault NA, et al. Prevention of HCC in hepatitis patients. Clin Liver Dis. 2020.

Holčapek M, et al. Lipidomics in hepatocellular carcinoma. Metabolites. 2021.

Tang A, et al. Epidemiology of hepatocellular carcinoma. Abdom Radiol. 2018.

Uzbekistan study on HDV prevalence. PubMed (2019), [PMID: 31505080].

Hepatitis D virus in Uzbekistan. ResearchGate (2020).

National screening data, Uzbekistan 2022–2024. PubMed (2024), [PMID: 40843480].

HBV prevalence in children after vaccination. PubMed (2023), [PMID: 39862544].

Nazirova Khusnijahon To‘lqinjon qizi. (2025). MICROBIOLOGICAL LINK BETWEEN HEPATITIS VIRUSES AND LIVER CANCER FORMATION. Ethiopian International Journal of Multidisciplinary Research, 12(08), 83–86